
AAVBC

American Academy
of Value Based Care

AAVBC Qualitative Platelet Disorder

Quick Reference Guide

2026

AAVBC Qualitative Platelet Disorder (QPD) Quick Reference Guide

Table of Contents

CLINICAL SNAPSHOT	3
RECOGNITION & DIAGNOSIS	4
Medicare screenings.....	4
Subtle Early Signs in Older Adults >65 yrs.....	5
Major Bleeding Red Flags - Immediate Action.....	6
Diagnostic thresholds for QPD.....	7
Clues to dig deeper.....	8
Common Oversights.....	9
Differential Diagnosis.....	9
Comorbidity Screening in Patients with Suspected or Confirmed QPD.....	10
Staging/severity.....	10
MEAT DOCUMENTATION ESSENTIALS	11
Clinical Documentation Elements.....	12
TREATMENT & REFERRAL QUICK GUIDE	13
Therapy escalation criteria.....	13
Non-Rx treatment documentation.....	13
When to refer.....	13
Follow-up timing.....	14
Patient education & adherence.....	14
Comorbidity management.....	15
Quality metrics tie-in.....	16
CODING REMINDERS AND CASE EXAMPLES	16
Specificity requirements.....	16
Annual Clinical Review and Confirmation.....	17
Good documentation is Comprehensive.....	17
EHR tips.....	17
Brief case examples.....	18
REFERENCES	18

1. CLINICAL SNAPSHOT

Definition: A Qualitative Platelet Disorder (QPD) is a bleeding disorder characterized by abnormal structure or function of the platelets themselves, despite the platelet count being normal or near-normal.¹

In QPDs, the platelets fail to perform one or more of their essential functions — adhesion, aggregation, activation, or secretion — leading to a defect in primary hemostasis and an increased tendency for mucocutaneous bleeding (e.g., easy bruising, nosebleeds, heavy menstrual bleeding).

There are inherited (e.g., Glanzmann thrombasthenia, Bernard-Soulier syndrome) and acquired causes (e.g., antiplatelet drugs) that lead to QPD.

ICD-10 codes: D69.1 — Qualitative platelet defects (encompasses any documented defect in platelet function).^{2,3}

For acquired or drug-induced cases, the coding rules rely on **combination coding**. Use **D69.1** for the **manifestation** (the platelet defect) and a separate code (e.g., from the **T36-T50** range (e.g., **drug-induced qualitative platelet dysfunction (T45.515A)**) for adverse drug effects or **N18** for CKD + **R58** (if bleeding) to specify the **etiology** (the cause)).^{2,3}

HCC/RAF V28 Mapping: HCC 112 (Coagulation Defects, Hemorrhagic Conditions, and Purpura) D69.1 with RAF (0.45).⁴

Prevalence:

- **Inherited qualitative platelet disorders** (e.g., Glanzmann thrombasthenia, Bernard-Soulier syndrome) are **extremely rare, <1 per 1,000,000 people**⁵
- **Acquired platelet dysfunction** is significantly more common, especially in older adults, and arises from chronic disease or medication effects
- There are roughly **56 million** U.S. residents ≥65. Surveys indicate that **more than half of seniors have at least one major QPD risk factor**⁶
- **30–35 million Americans** are currently living with significant acquired platelet dysfunction or high risk for it (based on risk associated with antiplatelet drug users)⁶
- **High prevalence of anti-platelet medication:** Up to **26%** of adults >60 in the U.S. regularly use NSAIDs⁶
- **High prevalence of CKD** (~34% of adults ≥65) induced QPD; presenting as uremia-related platelet dysfunction⁷

Cost Burden:

- QPDs carry a **disproportionately high economic impact** due to bleeding complications, transfusion dependence, and emergency utilization⁸
- QPD-related bleeding events; GI hemorrhage results in over 500,000 hospital admissions, over 2 million hospital days, \$5 billion in direct costs, and nearly 11,000 in-hospital deaths⁹

- **Inherited QPDs**; PMPY cost estimates exceed **\$40,000–\$60,000**, factoring in hospitalizations, platelet transfusions, rFVIIa use, and hematology visits (based on rare disease cost modeling and hemophilia analogues)⁸
- Each severe bleed episode requiring recombinant factor therapy can exceed **\$10,000–\$15,000** in acute treatment costs^{8,9}

2. RECOGNITION & DIAGNOSIS

Medicare screenings:^{1,10-13}

Test	Clinical need (who/when)	Coverage	CPT Code	Notes
Complete Blood Count (CBC) with Differential and Peripheral Smear	Initial assessment of bleeding/thrombosis risk	Covered for a wide range of signs, symptoms, and disease management (e.g., anemia, bleeding, general workup)	85025	Low billing risk
Platelet Count	Differentiate QPD from quantitative disorders	Covered, included in CBC	85025	A normal count is crucial for steering the workup toward qualitative tests (LTA, Flow Cytometry)
Peripheral Smear Review	Identify morphological clues	Covered when ordered to investigate an abnormal CBC or specific clinical signs	85060	Giant Platelets (Bernard-Soulier) is a strong indicator of medical necessity for advanced QPD testing
Coagulation Studies (PT and aPTT)	Rule out factor deficiencies	Highly covered for bleeding episodes, pre-surgical screening, or monitoring anticoagulant therapy	85610 (PT), 85730 (aPTT)	Normal results help narrow the differential diagnosis to a platelet problem, justifying subsequent (and higher-cost) platelet function tests
ISTH Bleeding Assessment Tool (ISTH-BAT)	Standardized symptom documentation. Strong documentation utility.	Clinical questionnaire/tool , not a billable laboratory test	—	A high score provides strong medical necessity documentation for ordering the more specialized and expensive CPT codes (like 85576, 88184) required for definitive QPD diagnosis

Test	Clinical need (who/when)	Coverage	CPT Code	Notes
Platelet function analysis (PFA-100/200 with CEPI & CADP cartridges)	Suspected platelet dysfunction (inherited or acquired); initial screen in adults with mucocutaneous bleeding	Covered when medically necessary; often requires correct ICD to avoid ABN (Some labs bill 85576 per cartridge)	85576 ×2 (per agonist)	PFA screens primary hemostasis/platelet dysfunction; not definitive
Light Transmission Aggregometry (LTA) with multiple agonists (ADP, EPI, COLL, AA, RIST)	Confirm/characterize qualitative platelet disorder; differentiate inherited subtypes; pre-op planning	Covered when medically necessary; documentation and correct ICD strongly influence payment; ABN may be needed if LCD not met	85576 (typically billed per agonist)	LTA is the gold standard for platelet function testing
Platelet glycoprotein analysis by flow cytometry (CD41/CD61 /CD42, etc.)	Suspected Bernard–Soulier (GPIb-IX-V deficiency) or Glanzmann (GPIIb/IIIa deficiency); abnormal LTA pattern when creatinine unreliable (e.g., low muscle mass, borderline eGFR)	Medicare covers flow cytometry under limited coverage articles — ensure indications meet local MAC policy	88184 (first marker), 88185 (each add'l), 88189 (physician interp, ≥16 markers)	Used to confirm receptor deficiencies after LTA
vWF panel (antigen, activity [ristocetin cofactor or GPIbM], ±FVIII; reflex to multimers when indicated)	Rule-out von Willebrand disease (most common platelet-type bleeding mimic) before labeling QPD	Medicare often applies limited coverage ; ABN may be required depending on MAC/panel. Verify lab CPTs and coverage.	Typical panel: 85240, 85245, 85246, 85730 ; reflex multimer analysis per lab	Required exclusion step in platelet-type bleeding workups

Note: **Consult your MAC's LCD** for specific covered ICD-10 codes. Documentation and correct ICD strongly influence payment.

Subtle Early Signs in Older Adults >65 yrs^{1,5,10-13}

- **Excessive Bruising (Ecchymoses)** → Often attributed to Senile Purpura (age-related skin fragility/vascular changes) or minor trauma; bruises are deep, raised, or appear in atypical locations without a clear injury history
- **Prolonged Superficial Bleeding** → Immediate, superficial, and mucosal bleeding. Minor cuts, shaves, or venipuncture that lasts >10 min and requires constant pressure
- **New or Worse Gingival Bleeding** → Easily dismissed as poor oral hygiene, gingivitis, or a side effect of dry mouth from medications

- **Iron Deficiency Anemia (New Onset)** → Often attributed to poor diet, chronic disease (e.g., kidney failure), or minor GI bleeding
- **Medication clues (very common in ≥65)** → Daily aspirin or chronic NSAIDs (OTC ibuprofen/naproxen) → reversible/irreversible platelet inhibition; P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) → additive mucocutaneous bleeding; SSRIs/SNRIs (e.g., sertraline, fluoxetine) → impaired platelet serotonin uptake and function; higher bleeding when combined with NSAIDs/antiplatelets
- **Comorbidity signals of acquired QPD** → Uremia (advanced CKD/ESRD), Advanced liver disease, Myeloproliferative neoplasms (ET/PV)

Geriatric risk factors^{1,5,6}

Factor	Risk Signal	Evidence Summary	Clinical Implication
Polypharmacy (≥5 medications)	High; Additive platelet inhibition and altered serotonin uptake from overlapping drug classes (NSAIDs + SSRIs ± antiplatelets).	~40% of older adults take ≥5 drugs; 10-15% receive ≥2 agents that impair platelet function	Perform annual med reconciliation; deprescribe NSAIDs/duplicate antiplatelets; coordinate with pharmacy
Chronic NSAID or daily aspirin use	High; Irreversible COX-1 inhibition → prolonged bleeding time	~25–35% of adults ≥65 use aspirin / NSAIDs daily; 4-fold ↑ risk of GI bleeding	Avoid routine use for primary prevention; substitute acetaminophen or topical agents; reinforce HEDIS PIM avoidance
SSRIs	High; Inhibit platelet serotonin uptake → defective aggregation; risk amplifies with antiplatelet/NSAID co-use	SSRI exposure increases GI-bleed risk 2-3×; risk rises >10× when combined with aspirin or NSAIDs	Flag SSRI + NSAID/antiplatelet combinations; consider mirtazapine or bupropion alternatives; reinforce GI protection (PPI) if therapy required
Dual antiplatelet or triple therapy (antiplatelet + antidepressant ± NSAID)	Synergistic impairment of primary hemostasis.	15–20% of patients on antiplatelets also take an SSRI/SNRI; markedly higher mucosal bleed rates	Re-evaluate cardiovascular indication; consult cardiology/psychiatry to simplify regimen
Advanced CKD (Stage 4–5/ESRD)	High; Uremic toxins inhibit platelet adhesion and aggregation	≥800 000 U.S. patients on dialysis; uremic bleeding common despite normal platelet counts	Optimize dialysis adequacy; avoid NSAIDs; consider DDAVP before procedures
Cirrhosis/advanced liver disease	High; Reduced synthesis of platelet-adhesion factors and concurrent thrombocytopenia	~1.5-2 million U.S. adults with cirrhosis; >70% show abnormal platelet function	Avoid NSAIDs/aspirin; correct vitamin K deficiency; coordinate pre-procedure hematology evaluation
Nutritional deficiencies (B₁₂, folate, iron)	Moderate; Altered platelet membrane fluidity ± anemia increasing bleeding tendency	Common in older adults with malabsorption or restricted diets	Screen annually; supplement deficiencies to mitigate additive risk

Major Bleeding Red Flags - Immediate Action^{1,10,12,13}

- **Gastrointestinal hemorrhage:** (melena, hematemesis, or hematochezia with tachycardia/hypotension); indicates systemic platelet dysfunction or drug-induced bleed compounded by comorbid disease; **admit for hemodynamic stabilization**
- **Intracranial or retinal bleeding:** (new severe headache, vision changes, confusion, focal deficits); suggests critical-site hemorrhage often worsened by antiplatelet/SSRI synergy; **immediate CT/MRI and hematology consult**
- **Uncontrolled post-procedural bleeding:** (surgery, dental, biopsy >2× expected duration); indicates inadequate primary hemostasis; typical in undiagnosed QPD or drug effect; **hold antiplatelet/NSAIDs and hematology consult**
- **Hematuria with clots or spontaneous soft-tissue hematomas:** Signifies systemic qualitative defect; can mimic thrombocytopenia; severe spontaneous mucocutaneous bleeding **warrants evaluation for qualitative defect even with normal platelet count**

Diagnostic thresholds for QPD¹⁰⁻¹³

Criterion	Test	Normal Reference Range (Approx)	Diagnostic QPD Pattern/Threshold	Clinical Rationale / Interpretation
Initial Screen	Platelet count	50–400 × 10 ⁹ /L	Normal or near-normal in QPD	Normal count with bleeding points to a qualitative defect; if <100 × 10 ⁹ /L, first exclude thrombocytopenia (quantitative)
	CBC (Hb, Hct, MCV) + Peripheral smear	Hb: ~12–16 g/dL (F), 13–17g/dL (M); MCV: 80–100fL	Often normal; may show iron-deficiency anemia if chronic mucosal loss; smear usually normal	Anemia supports chronic blood loss from mucocutaneous bleeding
	PT and aPTT	PT ~11–13.5s; aPTT ~25–35s	Both typically normal in isolated QPD	Normal PT/aPTT supports primary hemostasis (platelet) problem rather than coagulation factor deficiency
If indicated, secondary to initial screen	Platelet Function Analysis (PFA) (PFA-100/200) (CPT 85576)	Collagen/Epinephrine (C/EPI): 82–150 sec (CT) Collagen/ADP (C/ADP): 62–100 sec (CT)	Both C/EPI and C/ADP Closure Times (CT) are prolonged (>max normal)	Highly suggestive of severe adhesion/aggregation defect (e.g., Glanzmann's, Bernard-Soulier, severe uremia, or GpIIb/IIIa blockade)
			C/EPI CT is prolonged, but C/ADP CT is normal.	Highly sensitive for Aspirin/NSAID effect or a mild secretion/dense granule defect. A normal C/ADP rules out Glanzmann's or Bernard-Soulier syndrome
Gold Standard Confirmation	Light Transmission Aggregometry (LTA)(CPT 85576)	Maximal Aggregation (%): Varies by agonist, typically >60% for strong agonists (Thrombin, Collagen)	Absent / reduced aggregation to multiple strong agonists (Collagen, ADP, Thrombin) and	Glanzmann Thrombasthenia (GT): No aggregation to ADP, Collagen, Thrombin (fibrinogen receptor defect) confirm with flow

			severely reduced to Ristocetin	
--	--	--	--------------------------------	--

Criterion	Test	Normal Reference Range (Approx)	Diagnostic QPD Pattern/Threshold	Clinical Rationale / Interpretation
			Absent/reduced aggregation to Ristocetin, but normal aggregation to all other agonists	Bernard-Soulier Syndrome (BSS): Defect in GpIb-IX-V adhesion receptor. Also seen in severe Type 3 vWD
			Absence of a "second wave" of aggregation to ADP and Epinephrine.	Platelet Secretion/Storage Pool Defects (SPD): Platelets fail to release contents of dense granules (ADP, Serotonin) required for full aggregation
Secondary Screen (Exclusion)	von Willebrand Factor (vWF) Activity/Antigen (CPT 85246, 85240)	vWF Activity (Ristocetin Cofactor): 50-150%, <0.30IU/mL supports vWD regardless of bleeding; 0.30-0.50 requires bleeding phenotype/labs	Activity and/or Antigen levels are <30% (<50% in mild cases)	Required Exclusion: vWD is the most common bleeding disorder that <i>mimics</i> QPD. If vWF levels are low, the bleeding is primarily due to vWD, not an intrinsic platelet defect

Notes:

- **Do not diagnose inherited QPD** if vWD criteria are met; treat/document as vWD per **2021 ASH/ISTH**
- **Do not rely on PFA alone** — use it to **triage** to LTA; PFA is affected by anemia, thrombocytopenia, and sample handling¹
- **Always apply medication washouts** before LTA (aspirin 7–10d; clopidogrel 5–7d; non-aspirin NSAIDs 48–72h) to avoid false-positive qualitative defects¹
- **Use flow cytometry** to confirm **GT/BSS** when LTA patterns match; it improves specificity and audit defensibility

Clues to dig deeper^{1,12,13}

- **Recurrent mucocutaneous bleeding with normal platelet count:** Order PFA (CEPI/CADP) → LTA if prolonged; exclude vWD
- **Excessive bleeding after minor procedures** (*e.g., dental, cataract, skin biopsy*): → Failure of primary hemostasis despite normal coagulation tests → review aspirin/NSAID/SSRI use; repeat post-washout; if persistent → refer for LTA
- **Family history of bleeding with normal platelet counts:** Suggests inherited QPD (*e.g., Glanzmann, Bernard-Soulier*) → confirm via flow cytometry/genetic testing; offer family counseling

- **Bleeding after new medication start (SSRI, P2Y12 inhibitor, NSAID):** Strong temporal link to drug-induced platelet dysfunction → hold offending drug if safe; retest after 7–10 days to confirm reversibility
- **Concurrent anemia with normal coagulation studies:** May reflect chronic occult mucosal bleeding due to QPD → check stool guaiac and perform colorectal screens, review medications, evaluate for chronic low-grade bleed

Common Oversights

- **Failure to Rule Out Drug Effects:** Assuming the patient is aspirin-free based on history alone. Many OTC cold remedies, pain relievers, and even some PPIs can interfere with platelet function
- **Inaccurate LTA/PTA testing:** Failing to account for the 7-10 day washout period required for LTA/PFA
- **“Just aging”:** Dismissing mucocutaneous bleeding or easy bruising as solely due to Senile Purpura or age-related skin fragility, delaying the investigation of an underlying acquired QPD
- **Inadequate vWF Exclusion:** Failing to fully exclude vWD — the most common inherited bleeding disorder — before labeling a patient with a rare intrinsic QPD

Differential Diagnosis^{1,10-13}

Condition/Mimic	Key Clinical Clues	Recommended Evaluation	Notes
von Willebrand disease (vWD)	Mucocutaneous bleeding similar to QPD; family history; may have prolonged PFA and abnormal ristocetin response	vWF antigen & activity (GPIbM or RCo), Factor VIII, ± multimers	Most common inherited bleeding disorder
Thrombocytopenia (low platelet count)	Bleeding with low platelets (<100 × 10⁹/L) ; petechiae on lower limbs	CBC with smear to assess count/morphology; rule out ITP, drug-induced thrombocytopenia, marrow disease	Quantitative , not qualitative defect; D69.1 inappropriate
Drug-induced platelet dysfunction (NSAIDs, aspirin, P2Y12 inhibitors, SSRIs/SNRIs)	Onset after drug start; bruising, epistaxis, gum bleeding; normal platelet count.	Medication review, PFA (CEPI prolonged) ; repeat LTA after 7–10 day washout to confirm reversibility	Most frequent acquired QPD in elderly; document as drug-induced qualitative platelet dysfunction (T45.515A)
Senile purpura/skin fragility	Bruising limited to forearms, no mucosal bleeding, normal labs	Clinical diagnosis; labs optional if clear	Cosmetic, not hematologic; educate and avoid unnecessary QPD testing
Nutritional deficiencies (B₁₂, folate, iron)	Fatigue, pallor, macrocytosis/microcytosis, mild bruising	CBC, MCV, ferritin, B ₁₂ , folate	Correct deficiency before pursuing platelet studies; may coexist with QPD
Anticoagulant or DIC-related bleeding	Deep-tissue or delayed bleeding; prolonged PT/aPTT , falling fibrinogen	PT/INR, aPTT, fibrinogen, D-dimer	Coagulopathy rather than platelet disorder; treat underlying cause; not QPD

Bone marrow failure/MDS	Pancytopenia, fatigue, abnormal smear (dysplastic platelets)	CBC, smear, bone marrow biopsy if indicated	Qualitative + quantitative; consider hematology for cytogenetics
--------------------------------	--	---	--

Comorbidity Screening in Patients with Suspected or Confirmed QPD^{1,6,7,9,10}

Condition	Approximate Prevalence	Recommended Screening	Pathophysiology
Chronic Kidney Disease (Stage 4–5/ESRD)	Affects ~15% of U.S. adults; ~800 000 with ESRD (dialysis or transplant)	BUN, Creatinine, eGFR, CBC (Hb), PFA if bleeding	Uremic toxins inhibit platelet adhesion/aggregation; anemia worsens bleeding
Chronic Liver Disease/Cirrhosis	≈1.5-2 million U.S. adults (0.7 % prevalence) show cirrhosis; >70% have platelet dysfunction	AST/ALT, INR, Albumin, Platelet count, Abdominal US	Impaired thrombopoietin/vWF synthesis + hypersplenism
Myeloproliferative Neoplasms (ET/PV)	≈300 000 U.S. cases (incidence 2–3 / 100 000; median age >60 y)	CBC with diff, JAK2 mutation, vWF activity & antigen	Cytoreduce (e.g., hydroxyurea); check vWF annually; avoid unnecessary aspirin
Anemia (Iron/Folate/B₁₂ deficiency)	Affects ~10–12% of adults >65y; iron deficiency ≈9 million U.S. cases	CBC, Ferritin, Iron/TIBC, Folate, B ₁₂	Alters platelet membrane & oxygenation; amplifies mucosal bleeding
Diabetes Mellitus (Type 2)	Prevalence ≈14% of U.S. adults; >30% ≥65y	A1c, Fasting glucose, Lipid profile	Chronic hyperglycemia → glycation of platelet receptors & endothelial dysfunction.
Cardiovascular Disease on Antiplatelets	>50% of adults ≥65 use antiplatelets	Medication reconciliation, bleeding history, cardiology review	Polypharmacy (dual antiplatelet or triple therapy + SSRI/SNRI) → additive platelet inhibition
Psychiatric Disorders on SSRIs/SNRIs	~15% of older adults take SSRIs	Medication list, bleeding review)	Serotonin uptake blockade → reduced aggregation.
Nutritional/GI Disorders (Malabsorption, Bariatric Surgery, Celiac)	Malabsorption-related deficiency ≈1-2% of elderly	CBC, Iron studies, Stool guaiac, Endoscopy if indicated	Iron/B ₁₂ deficiency and occult GI bleeding
Nutritional deficiencies (e.g., B₁₂)	10-20% may have B ₁₂ insufficiency	Serum B ₁₂ , MMA if borderline; folate/Vit D optional	

Staging/severity:

Unlike conditions such as heart failure or COPD, **qualitative platelet disorders (QPDs) have no universally accepted staging system.** Severity is determined clinically rather than numerically, guided by the **frequency, duration, and anatomic site of bleeding**, and by the **level of medical intervention required.**

The **International Society on Thrombosis and Haemostasis Bleeding Assessment Tool (ISTH-BAT)** is the most widely used instrument to quantify bleeding history and can support severity classification.¹⁴

Severity Level	Clinical Features	Progression /Functional Markers	Management
Mild	<ul style="list-style-type: none"> • Infrequent or mild mucocutaneous bleeding (easy bruising, mild epistaxis, gingival oozing) • No spontaneous joint/muscle bleeds 	<ul style="list-style-type: none"> • Stable or minimal change over time. • ISTH-BAT ≤ 3 (women)/≤ 2 (men) • No increase in treatment need 	<ul style="list-style-type: none"> • Supportive care only. • Antifibrinolytics or DDAVP for minor procedures. • Low resource use (outpatient only)
Moderate	<ul style="list-style-type: none"> • Recurrent mucocutaneous bleeding (frequent/prolonged epistaxis, menorrhagia >7 days, post-dental oozing) • May require DDAVP or tranexamic acid 	<ul style="list-style-type: none"> • Increasing bleed frequency or duration. • New anemia or need for iron therapy • Escalation to pharmacologic intervention 	<ul style="list-style-type: none"> • Outpatient hematology management • Prophylaxis for procedures or menorrhagia • Moderate resource allocation (clinic visits, labs)
Severe	<ul style="list-style-type: none"> • Frequent spontaneous bleeding (joints, muscles, internal organs) • May present with hemarthrosis, GI, or intracranial hemorrhage 	<ul style="list-style-type: none"> • Transition from mucosal to deep-tissue bleeds • Requirement for repeated transfusions or rFVIIa • Drop in hemoglobin >2 g/dL or transfusion dependence 	<ul style="list-style-type: none"> • Managed at specialized bleeding-disorder centers. • Platelet transfusions or recombinant factor VIIa. • High resource utilization (hospitalization, multidisciplinary care)

3. MEAT DOCUMENTATION ESSENTIALS²

This documentation is highly specific for D69.1, It reflects a typical outpatient presentation of a **qualitative platelet defect** in an **older adult** with normal coagulation studies but abnormal bleeding risk — linked to chronic NSAID and SSRI exposure. The example integrates functional assessment, medication causality, lab confirmation, and clear treatment action; all requirements for compliant HCC capture.

Monitor: Monitoring focuses on bleeding pattern, medication exposure, and functional stability. Examples: "New forearm purpura noted; bruising occurs spontaneously without trauma; no mucosal bleeding reported." – "CBC with differential normal — platelets $242 \times 10^9/L$; PT 12.3 sec, aPTT 29 sec; consistent with qualitative defect, not thrombocytopenia." — "Medication reconciliation completed — chronic ibuprofen (400mg daily) and sertraline (50mg daily) identified as contributing agents." — "Monitoring ongoing; patient instructed to maintain bleeding log; recheck CBC and PFA in 3 months."

Evaluate: Assess the clinical consequence, functional status, and geriatric vulnerability. For example: "Evaluated fatigue, activity tolerance, and functional status — no syncope or overt anemia symptoms." — "ADL score 6/6; remains independent but at moderate fall risk due to osteoporosis." — "No history of surgical or dental bleeding; family history negative for inherited platelet disorders." — "Educated on fall precautions and avoidance of activities that may increase bruising risk."

Assess: Define the severity, control, and causal context: **"Acquired qualitative platelet defect (D69.1)** associated with chronic NSAID and SSRI exposure — consistent with drug-related platelet dysfunction." — "Normal coagulation studies; mild bruising phenotype; no deep-tissue or mucosal bleeding." — "Condition active but stable; reversible etiology identified." — "No evidence of inherited platelet disorder; hematology referral if bleeding recurs post-medication washout."

Treat: Treatment documents precise actions, medication changes, and safety precautions. Example phrasing: "Discontinued ibuprofen; transitioned to acetaminophen $\leq 2\text{g/day}$ for chronic pain management (dose adjusted for age and fall risk)." — "Reviewed SSRI therapy with psychiatry; plan to taper sertraline and consider switching to mirtazapine if bleeding persists." — "Patient advised to avoid all OTC NSAIDs, aspirin, and supplements known to impair platelet function (ginkgo, garlic, vitamin E)." — "Ordered repeat CBC, ferritin, and PFA at 3-month follow-up; continue observation unless new bleeding develops." — "Physical Exam: scattered forearm purpura, no petechiae, hemarthroses, or mucosal bleeding. ROS: denies melena, hematochezia, or hematuria."

Clinical Documentation Elements

Reflecting bleeding risk, causality, and active management.

- **Link to a care plan or action:** "QPD → bleeding-risk management plan initiated; patient educated on avoiding NSAIDs and scheduled hematology follow"
- **Onset & continuity:** Include diagnosis timing and disease persistence to establish longitudinal context; "Inherited QPD dx 2019 — persistent; last flare Aug 2024"
- **Causal and contributing factors:** When medication exposure or comorbid conditions contribute to platelet dysfunction, document the causal chain clearly to reflect mechanism and risk; "NSAID + SSRI use → acquired QPD → recurrent purpura → mild anemia"
- **Comorbidity linkage:** specify how coexisting conditions or therapies amplify bleeding risk "Cirrhosis + aspirin exposure → additive platelet inhibition → prolonged epistaxis episodes."
- **Active clinical status indicator:** Document qualitative platelet disorders as an active condition when ongoing, avoiding historical language that obscures current bleeding risk or management needs; avoid "history of"; use "Ongoing qualitative platelet defect, stable; no bleeding since July 2025"
- **Care plan and follow-up:** Link the diagnosis to an explicit management plan that includes education, medication adjustments, specialist follow-up, and monitoring intervals

Reframing Common Documentation Shortcuts

Replace	Prefer documenting...
"Stable QPD"	"No new bleeding; platelet count $250 \times 10^9/\text{L}$; ISTH-BAT unchanged (2 → 2)."
"History of platelet disorder"	"Current qualitative platelet dysfunction secondary to ESRD, managed with dialysis optimization."
"Bleeding tendency noted"	"Recurrent gum bleeding 2×/month, requiring tranexamic acid; active QPD."
"Labs normal"	"Platelet count $245 \times 10^9/\text{L}$, PT/aPTT normal — consistent with qualitative defect."

"Stable on meds"	"Continues antifibrinolytic therapy 1g BID; no bleeding since July 2025; adherent."
"Follow-up PRN"	"Follow-up q6 months with hematology; recheck LTA annually per consensus guidelines."

4. TREATMENT & REFERRAL QUICK GUIDE

Therapy escalation criteria:^{1,12,13}

Therapy Stage	Clinical Indicators /Trigger Points	Recommended Interventions
Tier 1 – Supportive /Preventive Management	<ul style="list-style-type: none"> Mild mucocutaneous bleeding only (e.g., easy bruising, mild epistaxis) ISTH-BAT ≤ 3 No spontaneous or post-procedural bleeds 	<ul style="list-style-type: none"> Avoid NSAIDs, aspirin, SSRIs/SNRIs Local measures for nosebleeds and gingival oozing. Antifibrinolytics (tranexamic acid or aminocaproic acid) for dental/minor procedures
Tier 2 – Expand Lab work-up and Tier 2 - Hematological referral for Advanced Therapy and Diagnosis	<ul style="list-style-type: none"> Recurrent mucocutaneous bleeding (≥ 3 episodes/yr) Menorrhagia or prolonged bleeding Post-procedure oozing or need for medical intervention ISTH-BAT 4-6 or rising trend Persistent bleeding despite medication washout or supportive therapy 	<ol style="list-style-type: none"> Escalate to hematology for advanced evaluation: <ul style="list-style-type: none"> Confirm with Light Transmission Aggregometry (LTA) \pm flow cytometry to classify QPD subtype (e.g., GT, BSS, storage pool defect) Exclude or co-diagnose von Willebrand disease via vWF antigen, activity, FVIII, and multimers Manage concurrent issues: <ul style="list-style-type: none"> Antifibrinolytics prophylactically for dental/surgical procedures Oral or IV iron repletion for chronic blood loss anemia Hormonal suppression (LNG-IUS or OCPs) for heavy menstrual bleeding

Non-Rx treatment documentation:

- Trauma Reduction** "Counseled on fall prevention measures (home safety, grab bars); instructed to avoid high-impact activities (e.g., contact sports, aggressive gardening)."
- Oral Hygiene** "Education provided on soft toothbrush use and gentle flossing to mitigate gingival bleeding risk."

When to refer:^{1,12,13}

Specialty	Clinical Trigger	Timeframe/Urgency
Hematology (Non-Urgent)	QPD confirmed by lab (PFA/LTA abnormal) but etiology is unclear; recurrent bleeding despite anti-fibrinolytics	Within 2-4 weeks (Outpatient)

Hematology (Urgent)	Need for platelet transfusion or DDAVP; unexplained acute bleeding; failure to correct hemostasis before urgent surgery	STAT consult (Inpatient/Emergency)
Nephrology	Acquired QPD due to CKD GFR <30 or any rapid, unexplained GFR decline	Within 1-2 weeks (for management of uremia/dialysis)
Gastroenterology	Unexplained chronic GI blood loss or iron deficiency anemia persistent despite Hgb 10.1 g/dL	Within 4 weeks (to rule out lesions/bowel disease/cancer/varices)

Follow-up timing:^{1,12,13}

- **Stable or Mild QPD** (no recent bleeding, ISTH-BAT ≤ 3): Reassess **every 6–12 months**; Review bleeding frequency, medication list, and CBC/ferritin annually; Update ISTH-BAT score and document “no new bleeding events.”
- **Moderate QPD** (Recurrent Mucosal Bleeding, ISTH-BAT 4–6): **Follow-up every 3–6 months**; Recheck CBC, ferritin, and review for new anemia or iron use; Document number of bleeding episodes and therapy use (DDAVP, antifibrinolytics); Schedule pre-procedure hematology consult for planned interventions
- **Severe/Refractory QPD** (ISTH-BAT ≥ 7 or Transfusion History): **Monthly or as clinically indicated** until stable; Ensure **care plan review q3mo** with multidisciplinary team (hematology, pharmacy, primary care)

Patient education & adherence:^{1,12,13}

- **Emphasize triggers to avoid:** Avoid **NSAIDs** (ibuprofen, naproxen), **aspirin**, and **herbal supplements** (ginkgo, garlic, ginseng)
- **Bleeding precautions:** Use a soft toothbrush, avoid contact sports, and wear gloves for yard or household work. Report **new bruising, prolonged bleeding**, or black/tarry stools immediately
- **Medication adherence:** Take prescribed **antifibrinolytics or DDAVP** exactly as directed — missing doses increases bleeding risk. If using **iron or hormonal therapy**, do not stop abruptly; recheck labs per schedule
- **Vaccinations and procedures:** Always **inform all providers** (dentist, surgeon) about QPD diagnosis before procedures. Keep a **medical alert card or bracelet** listing your condition and hematologist’s contact
- **Caregiver engagement:** Educate family on bleeding signs and medication timing
- **Address cost barriers:** Verify **Medicare Part D coverage** for tranexamic acid or DDAVP; explore assistance programs

Comorbidity management:^{1,12,13}

Condition	Key Clinical Risk /Interaction with QPD	Management & Monitoring Strategies
Chronic Kidney Disease (Stage 4–5/ESRD)	Uremic toxins impair platelet adhesion and aggregation; anemia amplifies bleeding	BUN, Creatinine, eGFR, CBC (Hb), PFA if bleeding
Chronic Liver Disease/Cirrhosis	Impaired thrombopoietin synthesis, hypersplenism, and reduced clotting factor production	<ul style="list-style-type: none"> • Manage portal hypertension; consider vitamin K if INR prolonged • Avoid NSAIDs/aspirin; use acetaminophen ≤2 g/day • Coordinate with hepatology before invasive procedures
Myeloproliferative Neoplasms (ET/PV)	Thrombocytosis (>1 million/ μ L) → acquired vWF deficiency → paradoxical bleeding	<ul style="list-style-type: none"> • Cytoreduction (hydroxyurea, interferon) • Monitor vWF activity annually • Avoid unnecessary aspirin if bleeding tendency present
Condition	Key Clinical Risk / Interaction with QPD	Management & Monitoring Strategies
Anemia (Iron /Folate/B₁₂ deficiency)	Chronic bleeding from QPD or comorbid GI disease worsens fatigue and hemostasis	<ul style="list-style-type: none"> • Correct deficiencies with oral or IV iron; repeat CBC/ferritin q3–6 mo • Treat bleeding source if identified
Diabetes Mellitus (Type 2)	Glycation impairs platelet signaling and increases oxidative stress	<ul style="list-style-type: none"> • Optimize A1c (<7.5% for elderly) • Use metformin with renal monitoring; avoid glyburide (hypoglycemia risk)
Cardiovascular Disease on Antiplatelets	Dual therapy or drug–drug interactions cause additive platelet inhibition	<ul style="list-style-type: none"> • Reassess ongoing need for dual antiplatelet therapy (DAPT) after 12 months • Consider monotherapy when safe • Add PPI for GI protection

Cost-smart Rx options:¹⁵

Drug/Formulation	Brand Name	Generic Name	Typical Cost Impact
Desmopressin Acetate (Nasal Spray)	DDAVP	Desmopressin Acetate (Injection, Tablet, Spray)	Significant savings. Generic desmopressin nasal spray can be 75-90% less expensive
DDAVP Melt (Tablet)	DDAVP Melt	Desmopressin Acetate (Orally Disintegrating Tablet)	Significant savings. Generic can be 75-90% less expensive
Tranexamic Acid	Cyklokapron, Lysteda	Tranexamic Acid	High savings. Generic forms are widely available and can cost 50% or less than the brand equivalent
Aminocaproic Acid	Amicar	Aminocaproic Acid	High savings. Generic is the low-cost standard. Brand cost can be extremely high
Recombinant Factor VIIa	NovoSeven	No generic equivalent	Costs are extremely high (often \$50,000+ per unit/dose for on-demand use).

			Utilization management must focus on appropriate dosing
--	--	--	---

Quality metrics tie-in:¹⁶

HEDIS/Quality Measure	Target	Impact
Potentially Harmful Drug-Disease Interactions in Older Adults (DDE)	Lower Rate ↓	Prevents inappropriate prescribing. QPDs often require avoiding certain Antiplatelet agents (e.g., Aspirin, NSAIDs) or high-risk drugs. Accurate QPD documentation serves as a necessary clinical flag to reduce DDE events
Transitions of Care (TRC)	Higher Rate ↑, prevent 30-day readmissions	Reduces readmissions. Uncontrolled bleeding (the major QPD complication) often leads to high-cost ER visits and hospitalizations. Effective discharge planning and management of QPDs (Tier 2/3 TRC compliance) prevents 30-day readmissions
Adherence to Medications for Chronic Conditions (Statin/Diabetes Meds)	Higher Rate ↑	Manages complex regimens. QPDs increase medication complexity (e.g., stopping Aspirin, starting Desmopressin). Improved care coordination driven by quality teams helps ensure adherence to necessary maintenance drugs while safely navigating bleeding risk
Emergency Department (ED) Utilization Rate	Lower Rate ↓	Avoids costly events. A critical, non-HEDIS metric in Value-Based care. Effective prophylactic management of QPDs (e.g., before dental work or during menses) avoids uncontrolled bleeding episodes that necessitate high-cost ED treatment and platelet transfusions

5. CODING REMINDERS AND CASE EXAMPLES

Specificity requirements:

- **Type/Etiology:** D69.1 Acquired (drug-induced, ESRD, cirrhosis) vs Inherited (very uncommon)(e.g., Glanzmann, Bernard-Soulier)
- **Activity:** Active, stable, or refractory (avoid "history of")
- **Associated condition/cause:** e.g., ESRD → uremic platelet dysfunction; aspirin use → drug-induced QPD
- **Complications:** Anemia (D62), GI bleeding (K92.2), menorrhagia (N92.0), transfusion dependence (Z79.899)
- **Coding linkage:** Acquired dysfunction → **code underlying cause (if known) + manifestation** (e.g., T45.515A [Adverse effect of antiplatelet] + D69.1 [Qualitative platelet defects] + K92.2 [GI bleed, unspecified])

Example ICD-10 combinations:

- Inherited QPD (Glanzmann): D69.1 + Z79.899 (chronic treatment use)
- Drug-induced dysfunction: T45.515A (adverse effect of antiplatelet) + K92.2 (GI bleed)

- Platelet dysfunction due to SSRI therapy: **D69.1** (Qualitative platelet defects, primary diagnosis) + **T43.205A** (Adverse effect of unspecified SSRI and TCA antidepressant, initial, secondary diagnosis)

Annual Clinical Review and Confirmation

Confirm QPD remains active, clinically relevant, and managed.

- **Annual review:** QPD must be reassessed once per calendar year via face-to-face or synchronous audio-video encounter, with MEAT documented by 12/31
- **Visit modality:** In-person or audio-video telehealth encounters qualify when platelet function, bleeding risk, and management are addressed
- **Clinical context:** Document active management annually (eg, monitoring platelet function, bleeding control strategies); For acquired QPD, re-state the underlying cause (e.g., secondary to ESRD) to reflect current pathophysiology

Good documentation is Comprehensive

Denial	Fix
"History of platelet disorder"	→ "Current qualitative platelet dysfunction due to ESRD — monitored and treated with DDAVP pre-procedure."
"QPD stable" (no MEAT)	→ "Monitored platelet function; no new bleeding; assessed for DDAVP response; continue conservative management."
"Bleeding disorder – unspecified"	→ Specify inherited vs. acquired and cause: "Acquired QPD from chronic NSAID exposure; NSAIDs stopped, follow-up in 6 months."
Missing linkage	→ Include cause → effect: "ESRD causing qualitative platelet dysfunction → chronic anemia → on ESA"
Non-specific labs	→ Add metrics: "Platelet count 245k, PT/aPTT normal, LTA abnormal — consistent with QPD."

EHR tips:

SmartPhrases/Templates:

- .QPDMEAT → Auto-fills Monitor/Evaluate/Assess/Treat lines for platelet disorders.
- .QPD_CAUSELINK → Inserts causality phrase ("secondary to ESRD/drug-induced")
- Problem List Flags → Mark *HCC_REQUIRED* for D69.1

Chronic Capture Alerts:

- Enable **Annual Wellness Visit prompt:** "Review chronic conditions for active management – QPD check."
- Add **Follow-up SmartSet:** CBC, ferritin, PTT/PT orders + bleeding assessment fields

- **Structured Fields:** ISTH-BAT score entry (flowsheet) for tracking; Checkbox for “Inherited vs. Acquired” to auto-suggest ICD-10 logic

Brief case examples:

Success — Acquired QPD (Drug-Induced, Primary Care)

76-year-old woman with osteoporosis, chronic NSAID use for arthritis pain, and sertraline (SSRI) for depression presents with spontaneous purpura on forearms. Platelet count normal ($240 \times 10^9/L$); PT/aPTT normal. PCP suspects acquired qualitative platelet defect due to medication effects. **Assessment:** “Acquired qualitative platelet defect (D69.1) secondary to chronic NSAID and SSRI exposure. Normal platelet count and coagulation studies confirm qualitative dysfunction.” **Plan:** “Stopped NSAIDs; switched to acetaminophen $\leq 2g/day$; psychiatric consult for SSRI taper; avoid aspirin/herbal antiplatelets; monitor bruising and repeat CBC + PFA in 3 mo.” **PE/ROS:** “Scattered forearm purpura, no petechiae, no mucosal bleeding.”

Pitfall — Missed QPD in Common Primary Care Setting (Post-Procedure Bleeding)

A 72-year-old man returns after tooth extraction with persistent gum bleeding. The chart lists only “Bleeding after dental procedure; on ibuprofen.” Labs: normal platelet count, normal PT/aPTT. **Fix/Corrected Documentation:** “Qualitative platelet dysfunction due to chronic NSAID exposure (D69.1). Normal platelet count and coagulation; consistent with drug-induced thrombocytopeny. NSAIDs stopped; tranexamic acid rinse prescribed; monitor bleeding, reassess in 2 weeks.”

REFERENCES:

1. Kaushansky K, Prchal JT, Burns LJ, et al. *Williams Hematology*. 10th ed. New York, NY: McGraw-Hill Education; 2021.
2. Centers for Medicare & Medicaid Services (CMS). *ICD-10-CM Official Guidelines for Coding and Reporting FY 2024*. Baltimore, MD: CMS; 2024. <https://icd10cmtool.cdc.gov/?fy=FY2025>. Accessed 2025.
3. Centers for Medicare & Medicaid Services (CMS). *Risk Adjustment Model Version 28 Technical Specifications*. CMS; 2024. <https://www.cms.gov/files/document/v28-technical-specifications.pdf>. Accessed 2025.
4. Centers for Medicare & Medicaid Services (CMS). *Medicare Advantage Capitation Rates and RAF Coefficients 2024*. Baltimore, MD: CMS; 2024. <https://www.cms.gov>. Accessed 2025.
5. Kim B. Diagnostic workup of inherited platelet disorders. *Blood Res*. 2022;57(S1):11-19. doi:10.5045/br.2022.2021223
6. Schaefer J, Barnes G, Singer D, et al. *Aspirin Use Among Older Adults*. University of Michigan National Poll on Healthy Aging. March 2024. <https://dx.doi.org/10.7302/22435>. Accessed 2025.
7. *USRDS 2023 Annual Data Report: Epidemiology of Kidney Disease in the United States*. National Institutes of Health, NIDDK; Bethesda, MD; 2023. <https://usrds-adr.niddk.nih.gov/>. Accessed 2025.
8. Connell NT, Caicedo J, Nieto N, et al. Real-world healthcare costs and resource utilization in patients with von Willebrand disease and angiodysplasia. *Expert Rev Pharmacoecon Outcomes Res*. 2023;23(6):691-699. doi:10.1080/14737167.2023.2211270

9. Peery AF, Dellon ES, Lund J, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: Update 2018. *Gastroenterology*. 2018;156(1):254-272.e11. doi:10.1053/j.gastro.2018.08.063
10. Functional Platelet Disorders. ARUP Consult® website. Updated 2025. <https://arupconsult.com/content/functional-platelet-disorders>. Accessed 2025.
11. Centers for Medicare & Medicaid Services. Medicare Coverage Database Search. Centers for Medicare & Medicaid Services website. <https://www.cms.gov/medicare-coverage-database/search.aspx>. Accessed 2025.
12. Hayward CPM, Moffat KA, Raby A, et al. Development of North American Consensus Guidelines for Medical Laboratories That Perform and Interpret Platelet Function Testing Using Light Transmission Aggregometry. *Am J Clin Pathol*. 2010;134(6):955-963. doi:10.1309/AJCP9V3RRVNZMKDS
13. Konkle BA, McLintock C, Kressner V, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. *Blood Adv*. 2021;5(1):301-325. doi:10.1182/bloodadvances.2020003264
14. International Society on Thrombosis and Haemostasis (ISTH). Reference Tools. ISTH website. Updated 2025. https://www.isth.org/page/reference_tools. Accessed 2025.
15. GoodRx. Prescription Drug Prices. GoodRx.com; 2024. <https://www.goodrx.com>. Accessed 2025.
16. National Committee for Quality Assurance. HEDIS Measures and Technical Resources. NCQA website. Published 2024. <https://www.ncqa.org/hedis/measures>. Accessed 2025.

Medical Disclaimer

The information provided by the American Academy of Value-Based Care (AAVBC) in this document, including but not limited to coding guidance, and related content, is intended for educational and informational purposes only. This content is designed to assist healthcare providers, organizations, and professionals in understanding and applying Value-Based Care principles, practices, and regulatory compliance standards.

AAVBC does not provide legal, clinical, or medical advice. The content presented should not be interpreted or relied upon as specific legal, medical, clinical, or professional guidance. While efforts are made to ensure the accuracy and currency of the information provided, AAVBC does not guarantee that the materials presented are complete, comprehensive, or without error.

Providers and healthcare professionals must independently evaluate all content and guidance presented herein in the context of applicable laws, regulations, clinical guidelines, payer policies, patient-specific conditions, and contraindications. Any treatments, procedures, diagnostic approaches, medications, or strategies discussed are illustrative and should not be directly applied without a thorough and independent review of current, evidence-based clinical resources, and regulatory requirements.

For coding, documentation, utilization management, quality measures (including STAR ratings), and compliance matters, users are responsible for consulting official guidelines issued by regulatory bodies, including but not limited to the Centers for Medicare & Medicaid Services (CMS), the American Medical Association (AMA), relevant state agencies, and other authoritative entities.

AAVBC expressly disclaims liability for any loss, claim, or damages arising directly or indirectly from the use or reliance on information provided in this document. Users should consult their organization's legal counsel, compliance officer, or qualified professional advisor for advice specific to their situation.

By accessing and using this document, you agree to AAVBC's terms and acknowledge that the use of the content is at your own risk and discretion.